French pharma firm denies drug risk cover up
May 10, 2011Sales and Marketing Mediator, Servier, drug safety
France’s second biggest pharma firm Servier has denied allegations it concealed risks associated with its diabetes drug Mediator (benfluorex). Research …
Sanofi name change sees Aventis dropped
May 9, 2011Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Sanofi, Sanofi-Aventis
Sanofi-Aventis will now just be known as Sanofi after the French pharma company’s shareholders agreed to change its name. Following …
Alliance warns of ‘dumbing down’ of NHS reforms
May 9, 2011NHS reforms
The leader of the NHS Alliance has warned the current ‘pause’ in the NHS reforms could result changes which ‘dumb …
Pfizer’s Revatio extends Europe PAH licence
May 9, 2011Sales and Marketing PAH, Pfizer, pulmonary arterial hypertension, revatio
Pfizer’s Revatio has been approved by European regulators for the treatment of pulmonary arterial hypertension (PAH) in children.The European Commission has …
Pharma manufacturing news in brief
May 9, 2011Manufacturing and Production
This week’s roundup has new contract awards for Aptuit and SAFC, plus facility updates from Cangene, Carbogen-Amcis and Aanjaneya Lifecare. …
Sanofi abandons $375m oral diabetes deal
May 9, 2011Sales and Marketing Metabolex, Sanofi, diabetes
Sanofi has terminated its $375 million deal with US biotech Metabolex to develop a novel oral anti-diabetic treatment. The French …
Pfizer signs Chinese commercial collaboration
May 9, 2011Sales and Marketing China, Pfizer, Shanghai Pharmaceutical Co
US giant Pfizer looks set to collaborate with Shanghai Pharmaceutical Co. on business opportunities in China. The potential partnership is …
Pay-for-delay deals up 60% in US
May 6, 2011Sales and Marketing FTC, generics
Deals to delay generic drugs from coming onto the US market have more than doubled. The Federal Trade Commission’s staff …
‘Weak’ evidence leads to NICE no for three leukaemia drugs
May 6, 2011Sales and Marketing Glivec, NICE, Sprycel, Tasigna
NICE has not recommended three major drugs for the rare blood cancer chronic myeloid leukaemia. In draft guidance on treating …
Novartis’ Afinitor wins landmark US approval
May 6, 2011Sales and Marketing Afinitor, Novartis
Novartis’ Afinitor has been approved in the US for the treatment of progressive neuroendocrine tumours of pancreatic origin (PNET) in …
Digital Pharma: Sanofi Pasteur MSD takes Quora approach to vaccines
May 6, 2011Medical Communications Digital Pharma blog, Sanofi Pasteur, vaccines
Sanofi Pasteur MSD is aiming to tackle myths and misconceptions about vaccines with a Quora-like online health information campaign in …
Jon Clark gains European leadership role at Nitrogen
May 6, 2011Medical Communications appointment, medical communications
Huntsworth Health has promoted Jon Clark to European managing director of its brand communications agency Nitrogen. He will report to …
Ogilvy picks Carsten Edwards to lead new market access business
May 6, 2011Medical Communications, Sales and Marketing Ogilvy, Ogilvy Healthworld Market Access, medical communications
Ogilvy Healthworld has appointed Carsten Edwards to head its new market access business. Edwards will be managing partner of market …
Thomas Lingelbach appointed chief executive of Intercell
May 5, 2011Research and Development appointment, research and development
Vienna-based biotech Intercell has appointed Thomas Lingelbach as chief executive with effect from 10 May. He has more than twenty …
INC Research to acquire Kendle
May 5, 2011Research and Development INC Research, Kendle, cros
Two contract research organisations INC Research and Kendle International are to merge to create a new major player in the …
Sanofi signs malaria research alliance
May 5, 2011Research and Development Medicines for Malaria Venture, Sanofi-Aventis, malaria
Sanofi-Aventis has signed a research deal with the Medicines for Malaria Venture charity. They will work together to identify, characterise …
Prostate cancer drug Zytiga gains US approval
May 5, 2011Sales and Marketing Centocor Ortho Biotech, Johnson & Johnson, Zytiga, prostate cancer
Zytiga a new treatment for the most hard to treat cases of prostate cancer has been approved in the US. …
Plavix sales plummet in England
May 5, 2011Sales and Marketing BMS, Plavix, Sanofi-Aventis, clopidogrel
GP prescriptions for Plavix saw a significant drop in England last year as doctors opted for cheaper generic forms of …
Debiopharm and Yale University to develop autoimmune treatment
May 5, 2011Research and Development Debiopharm, Yale University
Debiopharm is teaming up with researchers at Yale University to develop Debio 1036, a first-in-class inhibitor for autoimmune and inflammatory …
Pfizer sales flat as Lipitor revenues decline
May 4, 2011Sales and Marketing Pfizer
Pfizer’s sales decreased slightly in the first quarter after rising revenues in specialty care and emerging markets failed to offset …
Latest content
Scots neonatal innovations target hearing loss and earlier care
Agentis Health Group acquires Clinical Pharmacist Solutions
